EntryPoint Capital LLC Takes $266,000 Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

EntryPoint Capital LLC acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 14,105 shares of the company’s stock, valued at approximately $266,000.

Several other large investors have also added to or reduced their stakes in the business. Victory Capital Management Inc. bought a new stake in Nurix Therapeutics during the third quarter worth about $484,000. Intech Investment Management LLC bought a new stake in shares of Nurix Therapeutics during the 3rd quarter worth approximately $425,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at approximately $530,000. The Manufacturers Life Insurance Company grew its stake in shares of Nurix Therapeutics by 32.4% in the third quarter. The Manufacturers Life Insurance Company now owns 30,383 shares of the company’s stock valued at $683,000 after buying an additional 7,441 shares in the last quarter. Finally, FMR LLC increased its holdings in Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after buying an additional 511,256 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have commented on NRIX shares. BMO Capital Markets started coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price target for the company. Stifel Nicolaus lifted their price target on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. HC Wainwright upped their price objective on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Needham & Company LLC reduced their target price on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Finally, JPMorgan Chase & Co. decreased their target price on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $30.88.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $12.15 on Friday. The company has a market capitalization of $922.03 million, a P/E ratio of -4.20 and a beta of 2.18. The business’s 50 day simple moving average is $16.34 and its 200 day simple moving average is $20.40. Nurix Therapeutics, Inc. has a 1 year low of $11.90 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,811 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares in the company, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock valued at $213,449 in the last ninety days. 7.20% of the stock is currently owned by company insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.